Losigamone: A putative antiepileptic drug

George L. Morris, Susan Collins, Walter Bell, J. Todd Sahlroot, Margaret Matula, James Cereghino

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Losigamone (LSG) has shown anticonvulsant efficacy and low neurotoxicity in preclinical testing and has been tolerated in Phase I clinical trials. We report an open-label, add-on tolerability study of six ascending LSG dosage levels from 600 to 2,100 mg daily in patients receiving phenytoin (PHT), carbamazepine (CBZ), or combination PHT/CBZ. Dosage was escalated weekly, with assessment including reports of adverse events (AE), seizure diary, neurologic and physical examination, electrocardiogram (ECG), and laboratory tests. No serious AE were reported, and those most common AE were headache and dizziness. No significant alteration in PHT, CBZ, or CBZ-epoxide (CBZ-E) levels was noted. No clinically significant change in laboratory tests was noted. A median seizure reduction during LSG treatment as compared with baseline of 39% was achieved during the study. All 9 patients continued into an extension study, and 3 have remained seizure-free for as long as 2 years. Some brief increases in seizure frequency were evident at the 1,800- and 2,100-mg daily dosage levels. We conclude that continued evaluation of LSG for the treatment of partial seizures is indicated.

Original languageEnglish (US)
Pages (from-to)62-66
Number of pages5
JournalJournal of Epilepsy
Volume10
Issue number2
DOIs
StatePublished - Mar 4 1997

Fingerprint

losigame
Anticonvulsants
Seizures
Carbamazepine
Phenytoin
Clinical Trials, Phase I
Neurologic Examination
Dizziness
Physical Examination
Headache
Electrocardiography
Therapeutics

Keywords

  • Antiepileptic drugs
  • Controlled clinical trial
  • Drug toxicity
  • Losigamone
  • Partial seizures

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Morris, G. L., Collins, S., Bell, W., Sahlroot, J. T., Matula, M., & Cereghino, J. (1997). Losigamone: A putative antiepileptic drug. Journal of Epilepsy, 10(2), 62-66. https://doi.org/10.1016/S0896-6974(96)00085-0

Losigamone : A putative antiepileptic drug. / Morris, George L.; Collins, Susan; Bell, Walter; Sahlroot, J. Todd; Matula, Margaret; Cereghino, James.

In: Journal of Epilepsy, Vol. 10, No. 2, 04.03.1997, p. 62-66.

Research output: Contribution to journalArticle

Morris, GL, Collins, S, Bell, W, Sahlroot, JT, Matula, M & Cereghino, J 1997, 'Losigamone: A putative antiepileptic drug', Journal of Epilepsy, vol. 10, no. 2, pp. 62-66. https://doi.org/10.1016/S0896-6974(96)00085-0
Morris GL, Collins S, Bell W, Sahlroot JT, Matula M, Cereghino J. Losigamone: A putative antiepileptic drug. Journal of Epilepsy. 1997 Mar 4;10(2):62-66. https://doi.org/10.1016/S0896-6974(96)00085-0
Morris, George L. ; Collins, Susan ; Bell, Walter ; Sahlroot, J. Todd ; Matula, Margaret ; Cereghino, James. / Losigamone : A putative antiepileptic drug. In: Journal of Epilepsy. 1997 ; Vol. 10, No. 2. pp. 62-66.
@article{c2e0f8facded4d278f3c715138e16d20,
title = "Losigamone: A putative antiepileptic drug",
abstract = "Losigamone (LSG) has shown anticonvulsant efficacy and low neurotoxicity in preclinical testing and has been tolerated in Phase I clinical trials. We report an open-label, add-on tolerability study of six ascending LSG dosage levels from 600 to 2,100 mg daily in patients receiving phenytoin (PHT), carbamazepine (CBZ), or combination PHT/CBZ. Dosage was escalated weekly, with assessment including reports of adverse events (AE), seizure diary, neurologic and physical examination, electrocardiogram (ECG), and laboratory tests. No serious AE were reported, and those most common AE were headache and dizziness. No significant alteration in PHT, CBZ, or CBZ-epoxide (CBZ-E) levels was noted. No clinically significant change in laboratory tests was noted. A median seizure reduction during LSG treatment as compared with baseline of 39{\%} was achieved during the study. All 9 patients continued into an extension study, and 3 have remained seizure-free for as long as 2 years. Some brief increases in seizure frequency were evident at the 1,800- and 2,100-mg daily dosage levels. We conclude that continued evaluation of LSG for the treatment of partial seizures is indicated.",
keywords = "Antiepileptic drugs, Controlled clinical trial, Drug toxicity, Losigamone, Partial seizures",
author = "Morris, {George L.} and Susan Collins and Walter Bell and Sahlroot, {J. Todd} and Margaret Matula and James Cereghino",
year = "1997",
month = "3",
day = "4",
doi = "10.1016/S0896-6974(96)00085-0",
language = "English (US)",
volume = "10",
pages = "62--66",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Losigamone

T2 - A putative antiepileptic drug

AU - Morris, George L.

AU - Collins, Susan

AU - Bell, Walter

AU - Sahlroot, J. Todd

AU - Matula, Margaret

AU - Cereghino, James

PY - 1997/3/4

Y1 - 1997/3/4

N2 - Losigamone (LSG) has shown anticonvulsant efficacy and low neurotoxicity in preclinical testing and has been tolerated in Phase I clinical trials. We report an open-label, add-on tolerability study of six ascending LSG dosage levels from 600 to 2,100 mg daily in patients receiving phenytoin (PHT), carbamazepine (CBZ), or combination PHT/CBZ. Dosage was escalated weekly, with assessment including reports of adverse events (AE), seizure diary, neurologic and physical examination, electrocardiogram (ECG), and laboratory tests. No serious AE were reported, and those most common AE were headache and dizziness. No significant alteration in PHT, CBZ, or CBZ-epoxide (CBZ-E) levels was noted. No clinically significant change in laboratory tests was noted. A median seizure reduction during LSG treatment as compared with baseline of 39% was achieved during the study. All 9 patients continued into an extension study, and 3 have remained seizure-free for as long as 2 years. Some brief increases in seizure frequency were evident at the 1,800- and 2,100-mg daily dosage levels. We conclude that continued evaluation of LSG for the treatment of partial seizures is indicated.

AB - Losigamone (LSG) has shown anticonvulsant efficacy and low neurotoxicity in preclinical testing and has been tolerated in Phase I clinical trials. We report an open-label, add-on tolerability study of six ascending LSG dosage levels from 600 to 2,100 mg daily in patients receiving phenytoin (PHT), carbamazepine (CBZ), or combination PHT/CBZ. Dosage was escalated weekly, with assessment including reports of adverse events (AE), seizure diary, neurologic and physical examination, electrocardiogram (ECG), and laboratory tests. No serious AE were reported, and those most common AE were headache and dizziness. No significant alteration in PHT, CBZ, or CBZ-epoxide (CBZ-E) levels was noted. No clinically significant change in laboratory tests was noted. A median seizure reduction during LSG treatment as compared with baseline of 39% was achieved during the study. All 9 patients continued into an extension study, and 3 have remained seizure-free for as long as 2 years. Some brief increases in seizure frequency were evident at the 1,800- and 2,100-mg daily dosage levels. We conclude that continued evaluation of LSG for the treatment of partial seizures is indicated.

KW - Antiepileptic drugs

KW - Controlled clinical trial

KW - Drug toxicity

KW - Losigamone

KW - Partial seizures

UR - http://www.scopus.com/inward/record.url?scp=0031552134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031552134&partnerID=8YFLogxK

U2 - 10.1016/S0896-6974(96)00085-0

DO - 10.1016/S0896-6974(96)00085-0

M3 - Article

AN - SCOPUS:0031552134

VL - 10

SP - 62

EP - 66

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 2

ER -